Towards Healthcare
Non-Small Lung Carcinoma Market Drives 10.03% CAGR by 2034

Non-Small Lung Carcinoma Market Size, Trends, Bridging Innovation and Accessibility

Market insights predict the global non-small lung carcinoma industry will increase from USD 9.1 billion in 2024 to USD 23.67 billion by 2034, achieving a CAGR of 10.03%. Clinical research, development of new treatment options, and prevalence of NSCLC is driving the growth of the market.

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Non-Small Lung Carcinoma Market Assessment

  • Overview
  • Global Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • Squamous Cell Carcinoma
    • Large Cell Carcinoma
    • Adenocarcinoma
    • Others
  • Global Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy
  • Global Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Drug Store and Retail Pharmacy
    • Online Pharmacy
  • Global Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Region (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa

North America Non-Small Lung Carcinoma Market Assessment

  • Overview
  • North America Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • Squamous Cell Carcinoma
    • Large Cell Carcinoma
    • Adenocarcinoma
    • Others
  • North America Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy
  • North America Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Drug Store and Retail Pharmacy
    • Online Pharmacy

Europe Non-Small Lung Carcinoma Market Assessment

  • Overview
  • Europe Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • Squamous Cell Carcinoma
    • Large Cell Carcinoma
    • Adenocarcinoma
    • Others
  • Europe Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy
  • Europe Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Drug Store and Retail Pharmacy
    • Online Pharmacy

Asia Pacific Non-Small Lung Carcinoma Market Assessment

  • Overview
  • Asia Pacific Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • Squamous Cell Carcinoma
    • Large Cell Carcinoma
    • Adenocarcinoma
    • Others
  • Asia Pacific Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy
  • Asia Pacific Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Drug Store and Retail Pharmacy
    • Online Pharmacy

Latin America Non-Small Lung Carcinoma Market Assessment

  • Overview
  • Latin America Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • Squamous Cell Carcinoma
    • Large Cell Carcinoma
    • Adenocarcinoma
    • Others
  • Latin America Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy
  • Latin America Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Drug Store and Retail Pharmacy
    • Online Pharmacy

Middle East & Africa Non-Small Lung Carcinoma Market Assessment

  • Overview
  • Middle East & Africa Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • Squamous Cell Carcinoma
    • Large Cell Carcinoma
    • Adenocarcinoma
    • Others
  • Middle East & Africa Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy
  • Middle East & Africa Non-Small Lung Carcinoma Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Drug Store and Retail Pharmacy
    • Online Pharmacy

Company Profiles

  • Eli Lilly and Company
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Celgene Corporation
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Sanofi, Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Boehringer Ingelheim

Conclusion & Recommendations

  • Insight Code: 5155
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: April 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

Surgery, radiation therapy, chemoradiation therapy, combination therapy, targeted therapy, immunotherapy, systemic therapy, chemotherapy, adjuvant therapy.

Coughing that gets worse with time, coughing up blood, loss of appetite, fatigue, weight loss, wheezing, chest pain, trouble swallowing, face swelling, hoarseness and trouble breathing.

Technological advancements and R&D, including personalized cancer vaccines, immunotherapy, CRISPR technology, and microorganisms that live in the body for treatment, will improve cancer treatment.

World Health Organization, Government of Canada, Centers for Disease Control and Prevention, National Cancer Institute, FDA, American Lung Association, and American Cancer Society.